carlumab

Carlumab is a fully human IgG1 kappa monoclonal antibody that targets the chemokine C-C motif ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 (MCP-1). By binding to CCL2, carlumab inhibits its interaction with receptors such as CCR2 and CCR4 on monocytes and macrophages. This blockade disrupts the recruitment of these immune cells to sites of inflammation or tumor tissue, thereby reducing inflammation, fibrosis, angiogenesis, and tumor progression. Carlumab was developed primarily for oncology indications—including castration-resistant metastatic prostate cancer and solid tumors—as well as fibrotic and inflammatory diseases like idiopathic pulmonary fibrosis and systemic sclerosis. Despite promising preclinical results showing antitumor activity through inhibition of angiogenesis and modulation of the tumor microenvironment, clinical trials did not demonstrate sustained efficacy. The drug was discontinued in development by Janssen Biotech in 2012 due to limited success in clinical trials.

Other names

carlumabhuman monoclonal antibody targeting CC-chemokine ligand 2